Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | CASP6 | P55212 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | CLTC | Q00610 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8032702 | 0.84 | ALDH1A1 (0.33) | ALDH1A1CYP2C9CYP2C19CASP6HSD17B10 | |
| Lithium SCHEMBL4587867 | 0.83 | ALDH1A1 (0.32) | ALDH1A1CYP2C9CYP2C19CASP6HSD17B10 | |
| SCHEMBL7705622 | 0.83 | ALDH1A1 (0.32) | ALDH1A1CYP2C9CYP2C19CASP6HSD17B10 | |
| Lithium Ion SCHEMBL25250540 | 0.83 | CLTC (0.42) | CLTC | |
| Lithium Ion SCHEMBL29354256 | 0.83 | CLTC (0.42) | CLTC | |
| SCHEMBL21946061 | 0.78 | CLTC (0.36) | ALDH1A1CYP2C9CYP2C19CASP6HSD17B10 | |
| SCHEMBL21404284 | 0.77 | CLTC (0.40) | ALDH1A1CYP2C9CYP2C19CASP6HSD17B10 | |
| Ethylenediamine SCHEMBL21957845 | 0.76 | CLTC (0.39) | ALDH1A1CYP2C9CYP2C19CASP6HSD17B10 | |
| SCHEMBL27404612 | 0.76 | CLTC (0.39) | ALDH1A1CYP2C9CYP2C19CASP6HSD17B10 | |
| SCHEMBL1615000 | 0.75 | ALDH1A1 (0.39) | ALDH1A1CYP2C9CYP2C19CASP6HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3458571-B1 | PROCESS FOR GENERATING RENAL TUBULES | LEIBNIZ INST POLYMERFORSCHUNG DRESDEN EV (DE) | 2023-07-05 | — | — | EP | disclosed |
| US-11597909-B2 | Method for the formation of renal tubules | LEIBNIZ-INSTITUT FÜR POLYMER-FORSCHUNG DRESDEN E.V. (DE) | 2023-03-07 | — | — | US | disclosed |
| US-9549988-B2 | Pharmaceutical compounds targeted by MIF affinity-tethered moieties | RJS Biologics (US) | 2017-01-24 | — | — | US | disclosed |
| US-20150352217-A1 | Pharmaceutical Compounds Targeted by MIF Affinity-Tethered Moieties | RJS BIOLOGICS LLC | 2015-12-10 | — | — | US | disclosed |
| WO-2014148797-A1 | NOVEL ALBUMIN-COPPER BOND MEASUREMENT METHOD FOR MEASURING ALBUMIN IN MYOCARDIAL ISCHEMIA | 이화여자대학교 산학협력단 (KR) | 2014-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150352217-A1 | Pharmaceutical Compounds Targeted by MIF Affinity-Tethered Moieties | MIF, HMGB2, HMGB1 | ALDH1A1 2238/4885CYP2C9 3511/4885CYP2C19 2181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.